Neuropathix

Use of the Dual-action Neuroprotective Compound KLS-13019 to Treat Motor Impairment in a Preclinical Model of Parkinson’s Disease Study Rationale: Parkinson’s disease (PD) is associated with a loss of mitochondrial function and increased inflammation. A dual-action drug candidate, KLS-13019, both protects mitochondria from chemical stress and displays anti-inflammatory properties in cells and in rodents that develop a PD-lik...

We are thrilled to announce that Kannalife has received $1.49 million in funding from The Michael J. Fox Foundation for Parkinson's Research! This generous grant will support the development of our lead therapeutic, KLS-13019, which addresses neuroinflammation and mitochondrial dysfunction in Parkinson's disease. A great big thank you to our team and partners for their dedication and hard work. Together, we are making strides towards better treatments and improving lives. Neuropathix

Kannalife Secures Funding of $1.49 Million from The Michael J. Fox Foundation for Parkinson’s Research Funding of $1.49 million USD to support the development of KLS-13019 targeting neuroinflammation and mitochondrial dysfunction Kannalife has...

Dean Petkanas, CEO of Neuropathix and Kannalife Sciences interviewed from I am Biotech Convention - a dive deep into the groundbreaking work Kannalife is doing in the field of cannabinoid-based pharmaceuticals, particularly efforts in developing treatments for chemotherapy-induced peripheral neuropathy.

Exploring Neuroprotective Drugs with Dean Petkanas CEO of Kannalife Sciences In this episode of the Life Science Success Podcast, Dean Petkanas, co-founder of Kannalife Sciences, is interviewed at the Bio International Convention in S...

🎉 We're thrilled to share some exciting news! Neuropathix Kannalife Sciences, Inc. has been chosen by the National Institutes of Health (NIH) as one of the 30 NIH SEED Companies to present at the prestigious I am Biotech International Convention in San Diego. Mark your calendars for our CEO Dean Petkanas's presentation on Tuesday, June 4, 2024, at 4:30 PM in Company Presentation Theater 3. Plus, swing by the NIH booth #825 on Tuesday, June 4, 2024, at 11:56 AM for an up-close look.

A big thank you to NIH for recognizing our team's dedication to researching treatments for unmet medical needs.

Dean Petkanas Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support.

At BioPartnering event, it’s easy to find cheerleaders for (and critics of) state | ROI-NJ Dean Petkanas is the CEO of prerevenue Neuropathix, a Doylestown, Pennsylvania-based company, one of 90 that came to BioNJ’s BioPartnering Conference on Tuesday looking to make connections. And, if he’s looking for another job, he appears to be a prime candidate to be a spokesperson/cheerleader ...

🔬 New Research Alert! Neuropathix, Kannalife Sciences - Scientists uncover a link between KLS-13019 and the GPR55 receptor, shedding light on its promising role in reducing inflammatory markers associated with chemotherapy-induced peripheral neuropathy (CIPN). In contrast, cannabidiol (CBD) shows low efficacy, highlighting significant differences between the two compounds.

Our recent study in the Journal of Molecular Neuroscience investigates the anti-inflammatory actions of KLS-13019 and CBD in CIPN.

💡 Insights from this study pave the way for targeted therapies and innovative approaches to treating inflammation. Stay tuned.

📚 Read the full study here: https://rdcu.be/dFqru

rdcu.be

Please join Neuropathix on October 11, 2023 at the NIH Life Sciences Summit at the Alexandria Life Sciences Center in NYC to see our subsidiary Kannalife Sciences, take center stage!

We're proud to be only one of fifteen innovative, fundable, early-stage life sciences companies selected by NIH to present our breakthrough technology to treat neuropathic pain, inflammation and addiction.

https://lifesciencessummit.org/presenters-23/

Emerging Company Showcase – Life Sciences Summit Innovative, Fundable, Early Stage Opportunities Each company featured in the 2023 Emerging Company Showcase was nominated, reviewed and invited to present based upon their innovative science and the quality of their management team. They presented before a panel of ‘Pitch Doctors’, early stage V...

Neuropathix CEO Dean Petkanas pens Op-Ed on Why Opioids controlled the Pain Management Market and What's Next.

Why Opioids Controlled the Pain Management Market for So Long and for All the Wrong Reasons: Here’s What’s Next It’s no secret that the pain management market is booming.

Neuropathix Highlights Revenue Related to its Grant Award with NIH-NINDS

Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS 97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic PainDOYLESTOWN, PA / ACCESSWIRE / May 25, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a....

The new data from the CDC is staggering. The numbers from 2021 are alarming, 15% higher than 2020. 108,000 Americans died of a drug overdose in 2021. Addiction is real and so are these numbers.

At Neuropathix we are working on a treatment for pain that is a non-opioid, non-addictive alternative to current opioid medicines out there. In October, we received a three-year $2.97M grant award from National Institutes of Health (NIH) - HEAL Initiative (Helping to End Addiction Long-term) because they see promise in our drug candidate. Spread the word.

Record 108,000 Americans died of a drug overdose in 2021, CDC reports The Centers for Disease Control and Prevention said this was a 15 percent rise on the previous year, and marked the third year in a row that they had risen year-on-year.

Neuropathix CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding

Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO Dean Petkanas has issued a letter to its shareholders, providing commentary on the Company's recen...

CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
$NPTX